The Effect of Proton Pump Inhibitors on Glycated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus

Canadian Journal of Diabetes

Volumn 39, Issue 1, 2015, Pages 24-28

  Han, Na ^a   Oh, Minkyung ^b   Park, Su Min ^a   Kim, You Jeong ^a   Lee, Eun Ju ^a   Kim, Tae Kyoon ^a   Kim, Tae Nyun ^a   Kwon, Min Jeong ^a   Kim, Mi kyung ^a   Lee, Soon Hee ^a   Rhee, Byoung Doo ^a   Park, Jeong Hyun ^a  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

A1C; Gastrin; Proton pump inhibitor; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ESOMEPRAZOLE; GLITAZONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; ILAPRAZOLE; LANSOPRAZOLE; METFORMIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SULFONYLUREA; GASTRIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SOUTH KOREA; TREATMENT DURATION; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84921325609     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.10.008     Document Type: Article

References (23)

1. Kahn S.E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. JClin Endocrinol Metab 2001, 86:4047-4058.
2. Powers A.C. Diabetes mellitus. Pathogenesis. Harrison's principles of internal medicine 2012, 2968-2976. McGraw-Hill, New York, NY. 18th ed. D.L. Longo, D.L. Kasper, A.S. Fauci (Eds.).
3. Dockray G., Dimaline R., Varro A. Gastrin: Old hormone, new functions. Pflugers Arch 2005, 449:344-355.
4. Wolfe M.M., Soll A.H. The physiology of gastric acid secretion. NEngl J Med 1988, 319:1707-1715.
5. Suarez-Pinzon W.L., Lakey J.R., Brand S.J., et al. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β-cells from pancreatic duct cells and an increase in functional β-cell mass. JClin Endocrinol Metab 2005, 90:3401-3409.
6. Rooman I., Lardon J., Bouwens L. Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 2002, 51:686-690.
7. Boj-Carceller D. Proton pump inhibitors: Impact on glucose metabolism. Endocrine 2013, 43:22-32.
8. Bödvarsdóttir T.B., Hove K.D., Gotfredsen C.F., et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 2010, 53:2220-2223.
9. Singh P.K., Hota D., Dutta P., et al. Pantoprazole improves glycemic control in type 2 diabetes: A randomized, double-blind, placebo-controlled trial. JClin Endocrinol Metab 2012, 97:2105-2108.
10. Hove K.D., Færch K., Bödvarsdóttir T.B., et al. Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients-a retrospective analysis. Diabetes Res Clin Pract 2010, 90:72-74.
11. Mefford I.N., Wade E.U. Proton pump inhibitors as a treatment method for type II diabetes. Med Hypotheses 2009, 73:29-32.
12. Hove K.D., Brøns C., Færch K., et al. Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: A randomised double-blind prospective placebo-controlled study. Diabetologia 2013, 56:22-30.
13. Phadatare P.D., Chandrashekhar V.M. Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits. Mol Cell Biochem 2011, 354:135-140.
14. Crouch M.A., Mefford I.N., Wade E.U. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. JAm Board Fam Med 2012, 25:50-54.
15. Saurez-Pinzon W.L., Rabinoritch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice. Cell Transplant 2011, 20:1343-1349.
16. Trudeau W.L., McGuigan J.E. Serum gastrin levels in patients with peptic ulcer disease. Gastroenterology 1970, 59:6-12.
17. Ishihara M., Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol 2002, 444:209-215.
18. Zhang Z., Sun L.P., Gong Y.H., et al. Factors affecting the serum gastrin 17 level: An evidence-based analysis of 3906 serum samples among Chinese. JDig Dis 2007, 8:72-76.
19. Charlot M., Ahlehoff O., Norgaard M.L., et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: A nationwide cohort study. Ann Intern Med 2010, 153:378-386.
20. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953.
21. Lundell L., Miettinen P., Myrvold H.E., et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009, 7:1292-1298.
22. Galmiche J.P., Hatlebakk J., Attwood S., et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. JAMA 2011, 305:1969-1977.
23. Food and Drug Administration. FDA's safety reviews of Prilosec and Nexium find no evidence of increased rates of cardiac events. 2007. Accessed August 20, 2012. http://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm109037.htm.